154 related articles for article (PubMed ID: 17433276)
1. Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies.
Tímár J; Mészáros L; Ladányi A; Puskás LG; Rásó E
Cell Immunol; 2006 Dec; 244(2):154-7. PubMed ID: 17433276
[TBL] [Abstract][Full Text] [Related]
2. Microphthalmia transcription factor: a specific marker for malignant melanoma.
Vachtenheim J; Borovanský J
Prague Med Rep; 2004; 105(3):318-24. PubMed ID: 15782558
[TBL] [Abstract][Full Text] [Related]
3. Melanoma gene expression and clinical course.
Vourc'h-Jourdain M; Volteau C; Nguyen JM; Khammari A; Dreno B
Arch Dermatol Res; 2009 Oct; 301(9):673-9. PubMed ID: 19326132
[TBL] [Abstract][Full Text] [Related]
4. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.
Ugurel S; Houben R; Schrama D; Voigt H; Zapatka M; Schadendorf D; Bröcker EB; Becker JC
Clin Cancer Res; 2007 Nov; 13(21):6344-50. PubMed ID: 17975146
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
[TBL] [Abstract][Full Text] [Related]
6. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.
Goodall J; Carreira S; Denat L; Kobi D; Davidson I; Nuciforo P; Sturm RA; Larue L; Goding CR
Cancer Res; 2008 Oct; 68(19):7788-94. PubMed ID: 18829533
[TBL] [Abstract][Full Text] [Related]
7. Melanoma treatment update.
Tsao H; Sober AJ
Dermatol Clin; 2005 Apr; 23(2):323-33. PubMed ID: 15837158
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
[TBL] [Abstract][Full Text] [Related]
9. Genetic progression of metastatic melanoma.
Rodolfo M; Daniotti M; Vallacchi V
Cancer Lett; 2004 Oct; 214(2):133-47. PubMed ID: 15363539
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
Winnepenninckx V; van den Oord JJ
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1611-31. PubMed ID: 18020928
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical characteristics of melanoma.
Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
[TBL] [Abstract][Full Text] [Related]
12. New technologies used in the study of human melanoma.
Felsani A; Mileo AM; Maresca V; Picardo M; Paggi MG
Int Rev Cytol; 2007; 261():247-86. PubMed ID: 17560284
[TBL] [Abstract][Full Text] [Related]
13. New approaches in metastatic melanoma: biological and molecular targeted therapies.
Lejeune FJ; Rimoldi D; Speiser D
Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
Enk AH; Becker JC; Schuler G
J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
[TBL] [Abstract][Full Text] [Related]
15. [Melanoma: surface markers as the first point of targeted delivery of therapeutic genes in multilevel gene therapy].
Pleshkan VV; Zinov'eva MV; Sverdlov ED
Mol Biol (Mosk); 2011; 45(3):416-33. PubMed ID: 21790004
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunotherapy in the treatment of melanoma.
Faries MB
Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223
[TBL] [Abstract][Full Text] [Related]
17. Toward a molecular classification of melanoma.
Fecher LA; Cummings SD; Keefe MJ; Alani RM
J Clin Oncol; 2007 Apr; 25(12):1606-20. PubMed ID: 17443002
[TBL] [Abstract][Full Text] [Related]
18. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.
Koon HB; Atkins MB
Expert Rev Anticancer Ther; 2007 Jan; 7(1):79-88. PubMed ID: 17187522
[TBL] [Abstract][Full Text] [Related]
19. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck.
Morris LG; Wen YH; Nonaka D; DeLacure MD; Kutler DI; Huan Y; Wang BY
Head Neck; 2008 Jun; 30(6):771-5. PubMed ID: 18228523
[TBL] [Abstract][Full Text] [Related]
20. Novel MITF targets identified using a two-step DNA microarray strategy.
Hoek KS; Schlegel NC; Eichhoff OM; Widmer DS; Praetorius C; Einarsson SO; Valgeirsdottir S; Bergsteinsdottir K; Schepsky A; Dummer R; Steingrimsson E
Pigment Cell Melanoma Res; 2008 Dec; 21(6):665-76. PubMed ID: 19067971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
